Inhaled formulations for bacterial pneumonia: Strategies and advances in drug delivery
Abstract
Inhaled formulations have garnered significant interest in the treatment of bacterial pneumonia, as they deliver the drug directly to the site of infection in the lungs, providing high local drug concentrations that are typically unattainable with oral or intravenous therapies. Technologies for inhalation formulations that enable efficient sterilization, effective nebulization, maximized lung deposition, and reduced macrophage uptake are critical for successful inhaled drug delivery. Consequently, formulation strategies for inhalation drug delivery aimed at treating bacterial pneumonia are of paramount importance, encompassing factors such as the selection of bactericidal agents, drug carriers, aerodynamic diameter of particles, and particle morphology. The appropriate selection of formulation strategies is essential to overcoming the barriers of the respiratory tract, reaching the infected sites, releasing the bactericides, and penetrating deep into the biofilm to achieve effective eradication of bacterial pneumonia. This paper aims to classify recent inhaled preparations for bacterial pneumonia and to provide insights and perspectives for the development of novel inhaled delivery formulations targeting this condition.
Read the paper
Related studies
- Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Association between cord blood 25-hydroxyvitamin D concentrations and respiratory tract infections in the first 6 months of age in a Korean population: a birth cohort study (COCOA)
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.